Prospective Study
Copyright ©The Author(s) 2015.
World J Clin Cases. Apr 16, 2015; 3(4): 360-367
Published online Apr 16, 2015. doi: 10.12998/wjcc.v3.i4.360
Table 1 Demographic characteristics
Sugammadex (dose)Group A (n = 16)Group B (n = 16)P-value
Age (yr)43.6(SD 12.01)47.1(SD 14.18)0.46
Weight (kg)65.5(SD 11.22)60.9(SD 10.62)0.25
Height (cm)163.2(SD 4.76)160.1(SD 5.91)0.12
BMI (kg/m2)24.1(SD 3.56)23.2(SD 3.65)0.47
Intervention (time-minute)95.2(SD 26.91)94.7(SD 30.02)0.96
ASA (1-2)1.4(SD 0.51)1.2(SD 0.48)0.28
ASA 1an = 9(56.25%)n = 12(75.00%)0.23
Table 2 Train-of-four ratio studies
Group A (n = 14)
Group B (n = 14)
MeanMedianMeanMedianAssumed calculated interval (increased of 0% to 50% of median in group B)Estimated difference median by Hodges-Lehmann estimator95%CI
TOF ratio 0.9118.812996.61050 to 52.5240 to 45Differences not assumed
TOF ratio 0.896.710180.182.50 to 43.718-5 to 39Assumed
TOF ratio 0.778.49066.3650 to 32.510-10 to 35Assumed
Table 3 Adverse events
Adverse eventsGroup AGroup B
Arterial hypertension0%0%
Arterial hypotension0%0%
Bradycardia0%0%
Cough0%0%
Headache0%0%
Nausea6.20%6.20%
Pain6.20%6.20%
Residual neuromuscular blocking0%0%
Vomiting0%0%
Others0%6.20%